The study examined the effect of long-term control of hyperglycemia with a new SGLT2 inhibitor, luseogliflozin. Chronic treatment with luseogliflozin produced a sustained increase in glucose excretion and normalized blood glucose and HbA1c levels to the same level as seen in rats treated with insulin. It had no effect on blood pressure. T2DN rats treated with vehicle exhibited progressive proteinuria, a decline in glomerular filtration rate (GFR), focal glomerulosclerosis, renal fibrosis, and tubular necrosis. Control of hyperglycemia with luseogliflozin prevented the fall in GFR and reduced the degree of glomerular injury, renal fibrosis, and tubular necrosis. In contrast, control of hyperglycemia with insulin had no effect on the progression of renal disease in T2DN rats.
See article at J Pharmacol Exp Ther 2013, 345:464–472.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics